Claudio Abreu - Centene Corp President
| CNC Stock | USD 75.58 0.43 0.57% |
President
Claudio Abreu is Executive Vice President - Specialized Markets, Business Operations and Shared Services of Centene Corp since 2018.
| Tenure | 6 years |
| Address | Centene Plaza, Saint Louis, MO, United States, 63105 |
| Phone | 314 725 4477 |
| Web | https://www.centene.com |
Centene Corp Management Efficiency
The company has Return on Asset of 0.037 % which means that on every $100 spent on assets, it made $0.037 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1075 %, implying that it generated $0.1075 on every 100 dollars invested. Centene Corp's management efficiency ratios could be used to measure how well Centene Corp manages its routine affairs as well as how well it operates its assets and liabilities. At present, Centene Corp's Return On Assets are projected to increase slightly based on the last few years of reporting. At present, Centene Corp's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 6.4 B, whereas Net Tangible Assets are projected to grow to (1.4 B).Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Meghan Joyce | Oscar Health | 36 | |
| Jeff Barlow | Molina Healthcare | 58 | |
| Susan Diamond | Humana Inc | 50 | |
| Greg Allen | Cigna Corp | N/A | |
| Eric Palmer | Cigna Corp | 48 | |
| Marianne Short | UnitedHealth Group Incorporated | 68 | |
| James Clark | CVS Health Corp | 59 | |
| Bruce Perkins | Humana Inc | 59 | |
| Betty Assapimonwait | Humana Inc | N/A | |
| Joshua Flum | CVS Health Corp | 50 | |
| Prem Shah | CVS Health Corp | 41 | |
| James Woys | Molina Healthcare | 65 | |
| ALAN MUNEY | Cigna Corp | 63 | |
| Christopher MBA | Cigna Corp | N/A | |
| Christopher Hunter | Humana Inc | 52 | |
| William Fleming | Humana Inc | 53 | |
| Nicole Jones | Cigna Corp | 53 | |
| John Murabito | Cigna Corp | 62 | |
| George II | Humana Inc | 55 | |
| MPP MD | CVS Health Corp | N/A | |
| Alan Wheatley | Humana Inc | 51 | |
Management Performance
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.037 |
Centene Corp Leadership Team
Elected by the shareholders, the Centene Corp's board of directors comprises two types of representatives: Centene Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Centene. The board's role is to monitor Centene Corp's management team and ensure that shareholders' interests are well served. Centene Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Centene Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brent Layton, Executive Vice President, President - Health plans, Products, and International | ||
| James Dallas, Director | ||
| Vicki Escarra, Director | ||
| Colin Toney, Executive Vice President - Mergers and Acquisitions | ||
| H Dallas, Acting Chairman of the Board, Lead Independent Director | ||
| Katie Casso, Senior Vice President, Corporate Controller and Chief Accounting Officer | ||
| Leslie Norwalk, Independent Director | ||
| Cynthia Brinkley, Executive Vice President - Global Corporate Development | ||
| Jeffrey Schwaneke, Senior Vice President Chief Accounting Officer, Corporate Controller | ||
| Patrick Frawley, Senior Vice President - Social Responsibility | ||
| Lori Robinson, Independent Director | ||
| Jeffrey CPA, Chief Accounting Officer, Sr. VP and Corporate Controller | ||
| Suzy DePrizio, Senior Vice President Chief Marketing Officer | ||
| Shannon Susko, Senior Officer | ||
| Robert Ditmore, Presiding Independent Director | ||
| Robert Sanders, Executive Resources | ||
| Jennifer Gilligan, Senior Vice President of Investor Relations | ||
| Holly Benson, Executive Vice President | ||
| H Sanders, Executive Vice President - Global Human Resources | ||
| Sarah London, President - Health Care Enterprises and Executive Vice President - Advanced Technology | ||
| Brandy Burkhalter, Chief Operating Officer, Executive Vice President | ||
| Jessica Blume, Independent Director | ||
| Keith Williamson, Executive Vice President General Counsel, Secretary | ||
| Wayne DeVeydt, Independent Director | ||
| Kevin Counihan, Senior Vice President of Products | ||
| Christopher Isaak, Senior Vice President Corporate Controller and Chief Accounting Officer | ||
| William Scheffel, CFO, Executive Vice President Treasurer | ||
| David Thomas, Executive Vice President - Marketing | ||
| Ken Yamaguchi, Executive Vice President Chief Medical Officer | ||
| John Roberts, Independent Director | ||
| Rich Fisher, Senior Vice President, Medicare Chief Executive Officer | ||
| Matthew Snyder, Senior Vice President | ||
| Michael Neidorff, Chairman of the Board, President, Chief Executive Officer | ||
| Richard Gephardt, Independent Director | ||
| Bruce Laneis, Senior Vice President - Finance | ||
| Jim Murray, Chief Transformation Officer | ||
| Kenneth Fasola, President | ||
| David Steward, Independent Director | ||
| Christopher Koster, Executive Vice President, General Counsel, Company Secretary | ||
| Thomas Thompson, Independent Director | ||
| Jesse Hunter, Executive Vice President - Mergers and Acquisitions, Chief Strategy Officer | ||
| William Trubeck, Independent Director | ||
| Jonathan Dinesman, Executive Vice President - Government Relations | ||
| Pamela Joseph, Independent Director | ||
| Mark Brooks, Executive Vice President, Chief Information Officer | ||
| Kenneth Burdick, Executive Vice President - Markets & Products | ||
| Rone Baldwin, Executive VP of Insurance Group Bus. Unit | ||
| Edmund Kroll, Senior Vice President - Finance and Investor Relations | ||
| Christopher Coughlin, Independent Director | ||
| Frederick Eppinger, Independent Director | ||
| Theodore Samuels, Independent Director | ||
| Christopher Bowers, Senior Vice President - Health Plans | ||
| Orlando Ayala, Independent Director | ||
| Brian MBA, Chief Officer | ||
| Shannon Bagley, Executive Vice President, Chief Administrative Officer | ||
| Tommy Thompson, Independent Director | ||
| Claudio Abreu, Executive Vice President - Specialized Markets, Business Operations and Shared Services | ||
| Susan Smith, Chief Officer | ||
| Carol Goldman, Chief Admin. Officer and Executive VP | ||
| Andrew Asher, Chief Financial Officer, Executive Vice President | ||
| Ashlee Knuckey, Chief Officer |
Centene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Centene Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.037 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 39.54 B | ||||
| Shares Outstanding | 534.91 M | ||||
| Shares Owned By Insiders | 0.29 % | ||||
| Shares Owned By Institutions | 98.12 % | ||||
| Number Of Shares Shorted | 8.2 M | ||||
| Price To Earning | 20.27 X |
Pair Trading with Centene Corp
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Centene Corp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Centene Corp will appreciate offsetting losses from the drop in the long position's value.Moving together with Centene Stock
| 0.83 | FONR | Fonar | PairCorr |
Moving against Centene Stock
| 0.75 | IRIX | IRIDEX Financial Report 9th of May 2024 | PairCorr |
| 0.45 | GCTK | GlucoTrack | PairCorr |
The ability to find closely correlated positions to Centene Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Centene Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Centene Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Centene Corp to buy it.
The correlation of Centene Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Centene Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Centene Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Centene Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Centene Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Centene Stock refer to our How to Trade Centene Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Centene Stock analysis
When running Centene Corp's price analysis, check to measure Centene Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Centene Corp is operating at the current time. Most of Centene Corp's value examination focuses on studying past and present price action to predict the probability of Centene Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Centene Corp's price. Additionally, you may evaluate how the addition of Centene Corp to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is Centene Corp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Centene Corp. If investors know Centene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Centene Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.32) | Earnings Share 4.95 | Revenue Per Share 260.006 | Quarterly Revenue Growth 0.056 | Return On Assets 0.037 |
The market value of Centene Corp is measured differently than its book value, which is the value of Centene that is recorded on the company's balance sheet. Investors also form their own opinion of Centene Corp's value that differs from its market value or its book value, called intrinsic value, which is Centene Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Centene Corp's market value can be influenced by many factors that don't directly affect Centene Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Centene Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Centene Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Centene Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.